SCHEMBL3837519

SCHEMBL3837519

CCC(O)C(CC)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.42
CHRM1 P11229 1/20 0.42
AKR1A1 P14550 1/20 0.42
CHRM3 P20309 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42
ADRA1A P35348 1/20 0.42
HRH1 P35367 1/20 0.42
DRD3 P35462 1/20 0.42
SLC6A3 Q01959 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
TP53 P04637 1/20 0.38
CA2 P00918 1/20 0.36
MAPK1 P28482 1/20 0.36
GPR84 Q9NQS5 3/20 0.34
SLC1A3 P43003 2/20 0.34
SLC1A2 P43004 2/20 0.34
SLC1A1 P43005 2/20 0.34
FFAR1 O14842 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL687714 1.00 TDP1 (0.42) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL3064781 0.84 PDE4A (0.44) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL27677822 0.84 OR51E2 (0.42) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL1895730 0.84 PDE4A (0.44) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL3064788 0.84 PDE4A (0.44) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL3073651 0.84 PDE4A (0.44) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL5489376 0.82 PTGS1 (0.37) TDP1TP53
SCHEMBL13986496 0.82 TDP1 (0.48) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL9636422 0.82 TDP1 (0.48) TDP1CHRM1AKR1A1CHRM3HTR2A
SCHEMBL1000793 0.82 TDP1 (0.48) TDP1CHRM1AKR1A1CHRM3HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1059563-B1 Agent for reducing substrate dependence of resist WAKO PURE CHEM IND LTD (JP) 2006-08-09 EP claimed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-20120328536-A1 Taste Improving Substances QUEST INTERNATIONAL SERVICES B.V. (NL) 2012-12-27 US disclosed
US-8263161-B2 Taste improving substances QUEST INTERNATIONAL SERVICES B.V. (NL) 2012-09-11 US disclosed
EP-1854782-B1 Taste improving composition GIVAUDAN NEDERLAND SERVICES B (NL) 2009-09-30 EP disclosed
EP-1904640-B1 ASYMMETRIC REDUCTION OF 1,1,1-TRIFLUOROACETONE HOFFMANN LA ROCHE (CH) 2009-08-19 EP disclosed
EP-1904640-A2 ASYMMETRIC REDUCTION OF 1,1,1-TRIFLUOROACETONE F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
EP-1854782-A1 Taste improving composition Quest International Services B.V. (NL) 2007-11-14 EP disclosed
US-20070259089-A1 Taste improving substances QUEST INTERNATIONAL SERVICES B.V. (NL) 2007-11-08 US disclosed
US-7196234-B2 Asymmetric reduction of 1,1,1-trifluoroacetone HOFFMAN-LA ROCHE INC. (US) 2007-03-27 US disclosed
WO-2007006650-A2 ASYMMETRIC REDUCTION OF 1,1,1-TRIFLUOROACETONE F. HOFFMANN-LA ROCHE AG (CH) 2007-01-18 WO disclosed
US-20070009999-A1 Asymmetric reduction of 1,1,1-trifluoroacetone HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed
CN-1417186-A method of preparing 1,3-alkyldiol with 3-hydroxy ester SAMSUNG ELECTRONICS CO LTD (KR) 2003-05-14 CN disclosed
US-4561882-A HERBICIDES ZOECON CORPORATION (US) 1985-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120328536-A1 Taste Improving Substances TAS2R5, TAS2R3, TAS2R42 TDP1 1957/4885CHRM1 656/4885AKR1A1 1492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.